Drug Trial Radar · NCT05155839
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
Last checked: Nov 20, 2026Latest source record: Feb 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
108
Planned (sponsor's estimate)
Start
Jun 25, 2019
Primary completion
Oct 2022
Study completion Oct 2023
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of two parts. Phase Ia is a dose escalation study to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001. Phase Ib is a dose expansion study to assess the preliminary efficacy of MRG001 in patients with CD20-positive relapsed or refractory B-cell NHL at the confirmed RP2D. The safety, tolerability, pharmacokinetic (PK) and immunogenicity of MRG001 will be evaluated in both parts.
Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Interventions
MRG001Drug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: Baseline to 90 days after the last dose of study treatment.
- Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first treatment cycle (Day 1-21).
- Recommended Phase II Dose (RP2D)Time frame: Baseline to study completion (up to 15 months).
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen University Cancer Hospital
Guangzhou, Guangdong, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Harbin First Hospital
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.